The InSure® FIT™ Test and its unique Blue Brush Method make it easier to screen for colorectal cancer.
Clinical studies have shown that the InSure FIT test is highly sensitive for detecting blood in and around the stool, a key indicator of abnormalities in the colon and rectum that doctors use to help diagnose colorectal cancer.
The InSure FIT test has an 87% sensitivity for colorectal cancer.1 In a study of patients who were at average risk, high risk or had no symptoms at all, InSure FIT was found to have 33% greater sensitivity for colorectal cancer than a leading guaiac-based FOBT screening test.2
- An FOBT done during a digital rectal exam (DRE) in the doctor’s office is not sufficient for screening and is not recommended by American Cancer Society guidelines. If your doctor performs a DRE, you should ask him or her about the InSure FIT test.
- The guaiac-based FOBT tests have a risk of false positive results related to both red meat consumption and the use of certain medications around the time of sample collection, and therefore have drug and dietary restrictions. The InSure FIT test has no drug or dietary restrictions.2
InSure FIT Tests Make Annual Screening Easier1
The InSure FIT test kit provides a more convenient sample collection method, making annual colorectal cancer screening easier to fit into your life. Doctors often say that the best test is the one that is completed.
- The InSure FIT test is easier to use. To get a reliable sample, patients need only swish the toilet water above the stool with the convenient, long-handled blue brush.
- In one study, the InSure FIT test had as much as 66% better compliance compared to a leading guaiac-based FOBT.3 Here’s why:
- No other take-home colorectal cancer screening test has this convenient, water-based collection method – if you have used a paintbrush, you can use the InSure FIT.
- The InSure FIT tests can be used after meals and while taking any medications. There are no special food or medication restrictions.
- With the InSure FIT tests, samples are collected in the privacy of your home, then submitted to Quest Diagnostics or your doctor’s office for analysis.
That’s all there is to it.
- InSure FIT product inserts
- Smith A, Young GP, Cole SR, et al. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer. 2006;107:2152-2159. The study was funded in part by Enterix Inc. (through Enterix Australia Pty. Ltd), the manufacturer of InSure FIT. Enterix is now owned by Quest Diagnostics Incorporated. However, neither Enterix nor Quest Diagnostics participated in the data analysis or influence the conclusions reached by the authors. One of the authors, GP Young, is a consultant for Enterix Australia Pty. Ltd.
- Cole SR, Young GP, Esterman A, Cadd A, Morcom J. A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen 2003;10:117-122.